Pharmacodynamics MDA is a substrate of the serotonin, norepinephrine, dopamine, and vesicular monoamine transporters, as well as a TAAR1 agonist, and for these reasons acts as a reuptake inhibitor and releasing agent of serotonin, norepinephrine, and dopamine (that is, it is an ). It is also an agonist of the serotonin 5-HT2A, 5-HT2B, and 5-HT2C receptors and shows affinity for the α2A-, α2B-, and α2C-adrenergic receptors and serotonin 5-HT1A and 5-HT7 receptors. The (S)-optical isomer of MDA is more potent than the (R)-optical isomer as a psychostimulant, possessing greater affinity for the three monoamine transporters. In terms of the subjective and behavioral effects of MDA, it is thought that serotonin release is required for its empathogen-entactogen effects, release of dopamine and norepinephrine is responsible for its psychostimulant effects, dopamine release is necessary for its euphoriant (rewarding and addictive) effects, and direct agonism of the serotonin 5-HT2A receptor is causative of its psychedelic effects. Pharmacokinetics The duration of the drug has been reported as about 6 to 8 hours.
3,4-Methylenedioxyamphetamine
3,4-Methylenedioxy-N-ethylamphetamine
Methamphetamine
Cannabis
Cannabis 
Benzphetamine
Benzyl alcohol
Amphetamine